Power3 Medical Products, a company specializing in disease detection through the analysis of proteins, has filed for three patents on its blood test for the early detection of breast cancer. The Woodlands, TX-based company has identified 22 blood proteins with abnormal concentrations in women with breast cancer. The BC-SeraPro serum-based blood test analyzes these proteins to distinguish women with early stage breast cancer from those with benign tumors or normal breasts.
According to Ira L. Goldknopf, president of Power3 Medical, approximately 40,000 women in the U.S. die every year because their breast cancer is caught too late. About half of all cancers are wrongly identified as false negatives. More accurate testing is needed to detect breast cancer in its early, more treatable stages. Some companies working on breast cancer diagnostics include Stage I Diagnostics, Vizyontech Imaging, NeoMatrix, CYTYC Corporation, and Matritech.
Related news: Clarient Launches New Breast Cancer Test
